Arcus Biosciences Inc (RCUS)

$14.84

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Arcus Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 32.0M → 31.0M (in $), with an average decrease of 3.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -71.0M → -81.0M (in $), with an average decrease of 14.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 67.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 300.3%

Performance

  • $14.57
    $14.94
    $14.84
    downward going graph

    1.82%

    Downside

    Day's Volatility :2.48%

    Upside

    0.67%

    downward going graph
  • $12.95
    $25.47
    $14.84
    downward going graph

    12.74%

    Downside

    52 Weeks Volatility :49.16%

    Upside

    41.74%

    downward going graph

Returns

PeriodArcus Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-9.35%
-0.7%
0.0%
6 Months
-8.17%
6.6%
0.0%
1 Year
-20.56%
3.7%
-1.5%
3 Years
-53.71%
14.0%
-21.8%

Highlights

Market Capitalization
1.4B
Book Value
$6.12
Earnings Per Share (EPS)
-4.15
Wall Street Target Price
39.2
Profit Margin
-262.39%
Operating Margin TTM
-293.55%
Return On Assets TTM
-17.42%
Return On Equity TTM
-54.87%
Revenue TTM
117.0M
Revenue Per Share TTM
1.58
Quarterly Revenue Growth YOY
-8.799999999999999%
Gross Profit TTM
-176.0M
EBITDA
-332.0M
Diluted Eps TTM
-4.15
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.48
EPS Estimate Next Year
-4.24
EPS Estimate Current Quarter
-1.02
EPS Estimate Next Quarter
-0.96

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Arcus Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 164.15%

Current $14.84
Target $39.20

Company Financials

FY18Y/Y Change
Revenue
8.4M
↑ 491.15%
Net Income
-49.6M
↓ 6.57%
Net Profit Margin
-593.73%
↑ 3162.96%
FY19Y/Y Change
Revenue
15.0M
↑ 79.58%
Net Income
-75.9M
↑ 53.11%
Net Profit Margin
-506.21%
↑ 87.52%
FY20Y/Y Change
Revenue
77.5M
↑ 416.78%
Net Income
-116.7M
↑ 53.66%
Net Profit Margin
-150.52%
↑ 355.69%
FY21Y/Y Change
Revenue
382.9M
↑ 393.93%
Net Income
53.0M
↓ 145.42%
Net Profit Margin
13.84%
↑ 164.36%
FY22Y/Y Change
Revenue
112.0M
↓ 70.75%
Net Income
-267.0M
↓ 603.77%
Net Profit Margin
-238.39%
↓ 252.23%
FY23Y/Y Change
Revenue
117.0M
↑ 4.46%
Net Income
-307.0M
↑ 14.98%
Net Profit Margin
-262.39%
↓ 24.0%
Q3 FY22Q/Q Change
Revenue
33.6M
↑ 25.49%
Net Income
-60.4M
↓ 5.98%
Net Profit Margin
-179.99%
↑ 60.24%
Q4 FY22Q/Q Change
Revenue
345.0K
↓ 98.97%
Net Income
-67.0M
↑ 10.85%
Net Profit Margin
-19.4K%
↓ 19239.14%
Q1 FY23Q/Q Change
Revenue
25.0M
↑ 7146.38%
Net Income
-80.0M
↑ 19.41%
Net Profit Margin
-320.0%
↑ 19099.13%
Q2 FY23Q/Q Change
Revenue
29.0M
↑ 16.0%
Net Income
-75.0M
↓ 6.25%
Net Profit Margin
-258.62%
↑ 61.38%
Q3 FY23Q/Q Change
Revenue
32.0M
↑ 10.34%
Net Income
-71.0M
↓ 5.33%
Net Profit Margin
-221.88%
↑ 36.74%
Q4 FY23Q/Q Change
Revenue
31.0M
↓ 3.12%
Net Income
-81.0M
↑ 14.08%
Net Profit Margin
-261.29%
↓ 39.41%
FY18Y/Y Change
Total Assets
274.9M
↑ 44.33%
Total Liabilities
40.0M
↑ 9.19%
FY19Y/Y Change
Total Assets
203.1M
↓ 26.12%
Total Liabilities
39.3M
↓ 1.79%
FY20Y/Y Change
Total Assets
772.3M
↑ 280.23%
Total Liabilities
270.0M
↑ 587.55%
FY21Y/Y Change
Total Assets
1.6B
↑ 106.13%
Total Liabilities
750.4M
↑ 177.96%
FY22Y/Y Change
Total Assets
1.3B
↓ 15.51%
Total Liabilities
688.0M
↓ 8.32%
FY23Y/Y Change
Total Assets
1.1B
↓ 18.59%
Total Liabilities
633.0M
↓ 7.99%
Q3 FY22Q/Q Change
Total Assets
1.4B
↓ 5.62%
Total Liabilities
695.1M
↓ 4.7%
Q4 FY22Q/Q Change
Total Assets
1.3B
↓ 3.5%
Total Liabilities
688.0M
↓ 1.02%
Q1 FY23Q/Q Change
Total Assets
1.3B
↓ 6.77%
Total Liabilities
654.0M
↓ 4.94%
Q2 FY23Q/Q Change
Total Assets
1.2B
↓ 2.71%
Total Liabilities
654.0M
↑ 0.0%
Q3 FY23Q/Q Change
Total Assets
1.2B
↓ 2.38%
Total Liabilities
671.0M
↑ 2.6%
Q4 FY23Q/Q Change
Total Assets
1.1B
↓ 8.06%
Total Liabilities
633.0M
↓ 5.66%
FY18Y/Y Change
Operating Cash Flow
-43.0M
↑ 71.58%
Investing Cash Flow
-113.4M
↑ 131.18%
Financing Cash Flow
129.1M
↑ 20.19%
FY19Y/Y Change
Operating Cash Flow
-73.5M
↑ 70.86%
Investing Cash Flow
59.2M
↓ 152.2%
Financing Cash Flow
1.1M
↓ 99.13%
FY20Y/Y Change
Operating Cash Flow
111.2M
↓ 251.33%
Investing Cash Flow
-434.4M
↓ 833.58%
Financing Cash Flow
438.7M
↑ 38962.78%
FY21Y/Y Change
Operating Cash Flow
-256.2M
↓ 330.43%
Investing Cash Flow
-3.9M
↓ 99.11%
Financing Cash Flow
237.3M
↓ 45.9%
FY22Y/Y Change
Operating Cash Flow
438.0M
↓ 270.98%
Investing Cash Flow
-413.0M
↑ 10577.35%
Financing Cash Flow
33.0M
↓ 86.1%
Q3 FY22Q/Q Change
Operating Cash Flow
-81.0M
↑ 23.97%
Investing Cash Flow
23.4M
↓ 110.9%
Financing Cash Flow
2.5M
↓ 41.76%
Q4 FY22Q/Q Change
Operating Cash Flow
-69.7M
↓ 13.86%
Investing Cash Flow
46.8M
↑ 99.65%
Financing Cash Flow
11.2M
↑ 342.32%
Q1 FY23Q/Q Change
Operating Cash Flow
-98.0M
↑ 40.52%
Investing Cash Flow
129.0M
↑ 175.58%
Financing Cash Flow
1000.0K
↓ 91.07%
Q2 FY23Q/Q Change
Operating Cash Flow
-57.0M
↓ 41.84%
Investing Cash Flow
26.0M
↓ 79.84%
Financing Cash Flow
23.0M
↑ 2200.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-63.0M
↑ 10.53%
Investing Cash Flow
11.0M
↓ 57.69%
Financing Cash Flow
6.0M
↓ 73.91%

Technicals Summary

Sell

Neutral

Buy

Arcus Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arcus Biosciences Inc
Arcus Biosciences Inc
-13.82%
-8.17%
-20.56%
-53.71%
32.15%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arcus Biosciences Inc
Arcus Biosciences Inc
14.37
NA
NA
-3.48
-0.55
-0.17
NA
6.12
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arcus Biosciences Inc
Arcus Biosciences Inc
Buy
$1.4B
32.15%
14.37
-262.39%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    11.04%

  • FMR Inc

    5.20%

  • Vanguard Group Inc

    5.15%

  • State Street Corporation

    4.67%

  • Octagon Capital Advisors LP

    2.17%

  • Ameriprise Financial Inc

    1.80%

Company Information

arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be

Organization
Arcus Biosciences Inc
Employees
577
CEO
Dr. Terry J. Rosen Ph.D.
Industry
Health Technology

Discover More

FAQs